In this interview, CEO James Graham discusses Recce Pharmaceuticals’ recent commencement of a registrational Phase III study in Indonesia for its topical gel formulation of lead compound RECCE 327 (R327G) in the treatment of diabetic foot infections (DFIs). He also describes the commercial opportunity for treating DFIs and other bacterial skin infections in Indonesian and other Association of Southeast Asian Nation countries, where R327G commercialisation could start in 2026 upon positive data from this Phase III study. Mr Graham also discusses the most recent positive human clinical trial data for R327G in the treatment of skin infections, and Recce Pharmaceuticals’ upcoming plans to start a separate Australian Phase III study of R327G for the treatment of acute bacterial skin and skin structure infections, a broader indication than DFIs. He also elaborates on the company’s strategy for advancing R327 to US clinical development, including recent successes through its collaborations with the US Department of Defense.

Recce Pharmaceuticals is an innovative, clinical-stage Australian company developing novel, broad-spectrum synthetic polymer anti-infective drugs to treat several infectious diseases, including DFIs and other bacterial skin and skin structure infections, as well as sepsis and complex urinary tract infections.

Central nervous system (CNS) conditions are among the most significant unmet medical needs globally, with neurological conditions now one of the leading causes of disabilities, and having an impact on over 3.4 billion people worldwide. After decades of limited progress, the CNS field is experiencing a renaissance marked by novel technological advances that are overcoming barriers to effective drug development. Sophisticated blood-brain barrier crossing technologies are finally solving the fundamental delivery challenge, while AI-powered platforms are making unprecedented advances in drug discovery and biomarker identification. Most critically, the development of blood-based biomarkers is enabling early diagnosis and precision patient monitoring, addressing key issues that have historically limited CNS therapeutic success rates.

In this video, we speak with Stefan Weber, CEO of Newron Pharmaceuticals. We discuss the company’s registrational ENIGMA-TRS Phase III programme, the setting that evenamide is targeting and the licensing deals Newron has secured. Stefan also summarises the key milestones and catalysts that investors should watch out for across the next couple of years.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.